Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity—An Isobolographic Analysis

International Journal of Molecular Sciences

Anna Wawruszak¹  Joanna Kalafut¹  Adolfo Rivero-Muller¹  Marta Halasa¹  Andrzej Stepulak¹  JarogniewJ. Luszczki²  Karolina Okla³ 

[1] Department of Biochemistry and Molecular Biology, Medical University of Lublin, Chodzki 1 Street, 20-093 Lublin, Poland;Isobolographic Analysis Laboratory, Institute of Rural Health, Jaczewskiego 2 Street, 20-090 Lublin, Poland;The First Department of Gynecologic Oncology and Gynecology, Medical University of Lublin, Staszica 16 Street, 20-081 Lublin, Poland;

关键词: triple negative breast cancer (TNBC);    cisplatin (CDDP);    histone deacetylase inhibitors (HDIs);    valproic acid (VPA);    vorinostat (SAHA);    isobolographic analysis;    Notch1 receptor;   

DOI  :  10.3390/ijms20153663

来源: DOAJ

【 摘 要 】

The aim of this study was to investigate the influence of the Notch1 activity level on the pharmacological interaction between cisplatin (CDDP) and two histone deacetylase inhibitors (HDIs)—valproic acid (VPA) and vorinostat (SAHA) in the triple negative breast cancer (TNBC) cells. Stable breast cancer (BC) cell lines with increased and decreased activity of Notch1 were generated using a transfection method. The type of interaction between CDDP and the HDIs was determined by isobolographic analysis of cell proliferation in MDA-MB-231 cells with differential levels of Notch1 activity in vitro. The combination of CDDP/SAHA and CDDP/VPA in the MDA-MB-231 triple negative breast cancer (TNBC) cells with increased activity of Notch1, as well as CDDP/VPA in the MDA-MB-231 cells with decreased activity of Notch1, yielded an additive interaction, whereas additivity with a tendency towards antagonism was observed for the combination of CDDP/SAHA in MDA-MB-231 cells with the decreased activity of Notch1. Our studies demonstrated that SAHA and VPA might be considered as potential therapeutic agents in combination therapy with CDDP against TNBC with altered Notch1 activity.

【 授权许可】

Unknown